Autoantibodies to CD4 in HIV type 1-exposed seronegative individuals. 1996

S E Burastero, and D Gaffi, and L Lopalco, and G Tambussi, and B Borgonovo, and C De Santis, and C Abecasis, and P Robbioni, and A Gasparri, and A Lazzarin, and F Celada, and A G Siccardi, and A Beretta
San Raffaele Scientific Institute, Milan, Italy.

The aim of this study was to investigate the presence and the fine specificity of anti-CD4 autoantibodies in seronegative subjects sexually exposed to HIV-1. Anti-CD4 autoantibodies were previously detected in a fraction of HIV-1-seropositive individuals. Whole sera, purified IgG fractions, and supernatants of EBV-transformed lymphoblastoid cell lines were analyzed by means of ELISA, Western blot, and by competition assays using monoclonal antibodies with known fine specificities. Anti-CD4 antibodies were found in 6 of 18 individuals exposed to HIV-1 infection and who have been persistently seronegative. These antibodies inhibited HIV-1-driven syncytium formation, did not interfere with the CD4-gp120 interaction, and competed for CD4 binding with two of three anti-CD4 monoclonals with known fine specificities. Moreover, autoantibodies with the same fine specificities were found in the supernatants of oligoclonal EBV-transformed B cell lines derived from these individuals. At variance, in the HIV-1-positive patients included in our study, the anti-CD4 antibody response was directed to a broader panel of epitopes, including those involved in CD4-gp120 interactions. In conclusion, anti-CD4 antibodies specific for defined epitopes of the CD4 molecule are generated in the course of an early immune response to HIV-1 antigens in the absence of other signs of infection, as they can be detected by conventional methods. These autoantibodies may play a protective role either alone or in association with other cellular and humoral factors.

UI MeSH Term Description Entries
D008297 Male Males
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D006679 HIV Seropositivity Development of neutralizing antibodies in individuals who have been exposed to the human immunodeficiency virus (HIV/HTLV-III/LAV). AIDS Seroconversion,AIDS Seropositivity,Anti-HIV Positivity,HIV Antibody Positivity,HIV Seroconversion,HTLV-III Seroconversion,HTLV-III Seropositivity,AIDS Seroconversions,AIDS Seropositivities,Anti HIV Positivity,Anti-HIV Positivities,Antibody Positivities, HIV,Antibody Positivity, HIV,HIV Antibody Positivities,HIV Seroconversions,HIV Seropositivities,HTLV III Seroconversion,HTLV III Seropositivity,HTLV-III Seroconversions,HTLV-III Seropositivities,Positivities, Anti-HIV,Positivities, HIV Antibody,Positivity, Anti-HIV,Positivity, HIV Antibody,Seroconversion, AIDS,Seroconversion, HIV,Seroconversion, HTLV-III,Seroconversions, AIDS,Seroconversions, HIV,Seroconversions, HTLV-III,Seropositivities, AIDS,Seropositivities, HIV,Seropositivities, HTLV-III,Seropositivity, AIDS,Seropositivity, HIV,Seropositivity, HTLV-III
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001323 Autoantibodies Antibodies that react with self-antigens (AUTOANTIGENS) of the organism that produced them. Autoantibody
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor
D015153 Blotting, Western Identification of proteins or peptides that have been electrophoretically separated by blot transferring from the electrophoresis gel to strips of nitrocellulose paper, followed by labeling with antibody probes. Immunoblotting, Western,Western Blotting,Western Immunoblotting,Blot, Western,Immunoblot, Western,Western Blot,Western Immunoblot,Blots, Western,Blottings, Western,Immunoblots, Western,Immunoblottings, Western,Western Blots,Western Blottings,Western Immunoblots,Western Immunoblottings
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015704 CD4 Antigens 55-kDa antigens found on HELPER-INDUCER T-LYMPHOCYTES and on a variety of other immune cell types. They are members of the immunoglobulin supergene family and are implicated as associative recognition elements in MAJOR HISTOCOMPATIBILITY COMPLEX class II-restricted immune responses. On T-lymphocytes they define the helper/inducer subset. T4 antigens also serve as INTERLEUKIN-15 receptors and bind to the HIV receptors, binding directly to the HIV ENVELOPE PROTEIN GP120. Antigens, CD4,CD4 Molecule,CD4 Receptor,CD4 Receptors,Receptors, CD4,T4 Antigens, T-Cell,CD4 Antigen,Receptors, Surface CD4,Surface CD4 Receptor,Antigen, CD4,Antigens, T-Cell T4,CD4 Receptor, Surface,CD4 Receptors, Surface,Receptor, CD4,Surface CD4 Receptors,T-Cell T4 Antigens,T4 Antigens, T Cell
D018023 HIV Seronegativity Immune status consisting of non-production of HIV antibodies, as determined by various serological tests. HTLV-III Seronegativity,HIV Seronegativities,HTLV III Seronegativity,HTLV-III Seronegativities,Seronegativities, HIV,Seronegativities, HTLV-III,Seronegativity, HIV,Seronegativity, HTLV-III

Related Publications

S E Burastero, and D Gaffi, and L Lopalco, and G Tambussi, and B Borgonovo, and C De Santis, and C Abecasis, and P Robbioni, and A Gasparri, and A Lazzarin, and F Celada, and A G Siccardi, and A Beretta
January 2004, AIDS research and human retroviruses,
S E Burastero, and D Gaffi, and L Lopalco, and G Tambussi, and B Borgonovo, and C De Santis, and C Abecasis, and P Robbioni, and A Gasparri, and A Lazzarin, and F Celada, and A G Siccardi, and A Beretta
October 2006, Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae,
S E Burastero, and D Gaffi, and L Lopalco, and G Tambussi, and B Borgonovo, and C De Santis, and C Abecasis, and P Robbioni, and A Gasparri, and A Lazzarin, and F Celada, and A G Siccardi, and A Beretta
October 2013, AIDS research and human retroviruses,
S E Burastero, and D Gaffi, and L Lopalco, and G Tambussi, and B Borgonovo, and C De Santis, and C Abecasis, and P Robbioni, and A Gasparri, and A Lazzarin, and F Celada, and A G Siccardi, and A Beretta
March 2010, Journal of immunology (Baltimore, Md. : 1950),
S E Burastero, and D Gaffi, and L Lopalco, and G Tambussi, and B Borgonovo, and C De Santis, and C Abecasis, and P Robbioni, and A Gasparri, and A Lazzarin, and F Celada, and A G Siccardi, and A Beretta
January 2000, AIDS research and human retroviruses,
S E Burastero, and D Gaffi, and L Lopalco, and G Tambussi, and B Borgonovo, and C De Santis, and C Abecasis, and P Robbioni, and A Gasparri, and A Lazzarin, and F Celada, and A G Siccardi, and A Beretta
November 2023, iScience,
S E Burastero, and D Gaffi, and L Lopalco, and G Tambussi, and B Borgonovo, and C De Santis, and C Abecasis, and P Robbioni, and A Gasparri, and A Lazzarin, and F Celada, and A G Siccardi, and A Beretta
November 2012, AIDS (London, England),
S E Burastero, and D Gaffi, and L Lopalco, and G Tambussi, and B Borgonovo, and C De Santis, and C Abecasis, and P Robbioni, and A Gasparri, and A Lazzarin, and F Celada, and A G Siccardi, and A Beretta
May 2004, The Journal of infectious diseases,
S E Burastero, and D Gaffi, and L Lopalco, and G Tambussi, and B Borgonovo, and C De Santis, and C Abecasis, and P Robbioni, and A Gasparri, and A Lazzarin, and F Celada, and A G Siccardi, and A Beretta
January 2009, AIDS (London, England),
S E Burastero, and D Gaffi, and L Lopalco, and G Tambussi, and B Borgonovo, and C De Santis, and C Abecasis, and P Robbioni, and A Gasparri, and A Lazzarin, and F Celada, and A G Siccardi, and A Beretta
July 2009, AIDS (London, England),
Copied contents to your clipboard!